EAAT2 modulators(solute carrier family 1 member 2 modulators), NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists), Nav1.5 blockers(Sodium channel protein type V alpha subunit blockers)

Therapeutic Areas

Nervous System DiseasesCongenital DisordersOther Diseases+ [3]

Active Indication

Machado-Joseph DiseaseObsessive-Compulsive DisorderSpinocerebellar Ataxia 10+ [5]

Inactive Indication

Alzheimer DiseaseGeneralized anxiety disorderMetastatic melanoma

Originator Organization

Yale University

Active Organization

Biohaven Pharmaceuticals, Inc.

Baiaoxin Management (Shanghai) Co., Ltd.Biohaven Asia Pacific Ltd.

+ [4]

Inactive Organization-

License Organization-

Drug Highest PhaseNDA/BLA

First Approval Date-

RegulationPriority Review (United States), Fast Track (United States), Orphan Drug (United States)

Structure/Sequence

Molecular FormulaC15H17ClF3N5O4S

InChIKeyZRZLEMQBDKNTLJ-UHFFFAOYSA-N

CAS Registry1926204-76-3

Clinical Trials associated with Trigriluzole

NCT06552260

/ RecruitingEarly Phase 1IIT

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

This research study is studying troriluzole as a possible treatment for recurrent glioblastoma.
The name of the study drug involved in this research study is:
-Troriluzole (a tripeptide prodrug of riluzole)

Start Date19 Feb 2025

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+2]

CTR20213162

/ CompletedPhase 1

一项在中国健康受试者中评Troriluzole（BHV-4157）280mg单次和多次给药后的安全性、耐受性和药代动力学特征的I期、随机、双盲、安慰剂对照研究

[Translation] A Phase I, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic characteristics of Troriluzole (BHV-4157) 280 mg after single and multiple doses in healthy Chinese subjects

主要目的：评估在中国健康受试者中单次（280 mg）和多次（280 mg/日，连续5天）给药Troriluzole后的安全性和耐受性。次要目的：评估在中国健康受试者中单次（280 mg）和多次（280 mg/日，连续5天）给药Troriluzole后利鲁唑的药代动力学（PK）特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of troriluzole after single (280 mg) and multiple (280 mg/day, 5 consecutive days) administration in healthy Chinese subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of riluzole after single (280 mg) and multiple (280 mg/day, 5 consecutive days) administration of troriluzole in healthy Chinese subjects.

Start Date03 Mar 2022

Sponsor / Collaborator

BioShin Ltd.

[+2]

NCT04899921

/ TerminatedPhase 2IIT

A Blinded, Randomized Phase 2 Study of Troriluzole in Combination With Ipilimumab and Nivolumab in Patients With Melanoma Brain Metastases Previously Treated With Anti-PD-1 Therapy

The purpose of this research is to test the safety and effectiveness of the investigational combination of Troriluzole, ipilimumab, and nivolumab, and to learn whether this combination works in treating melanoma that has spread to the brain.

Start Date30 Jun 2021

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+1]

100 Clinical Results associated with Trigriluzole

100 Translational Medicine associated with Trigriluzole

100 Patents (Medical) associated with Trigriluzole

Literatures (Medical) associated with Trigriluzole

01 Apr 2025·Neurology and Therapy

Measurement Properties of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia

Article

Author: Beiner, Melissa Wolfe ; L'Italien, Gilbert ; Coric, Vlad ; Subramony, Sub ; Synofzik, Matthis ; Popoff, Evan ; Powell, Lauren C ; Potashman, Michele H ; Schmahmann, Jeremy ; Mackenzie, Ainsley

INTRODUCTION:

The Friedreich Ataxia Rating Scale-Activities of Daily Living (FARS-ADL) is a valid, highly utilized measure for assessing ADL impacts in patients with Friedreich ataxia. We provide evidence of the psychometric validity of the FARS-ADL in two cohorts of patients with spinocerebellar ataxia (SCA).

METHODS:

Using data from a cohort of real-world subjects with SCA (recruited at Massachusetts General Hospital [MGH]; n = 33) and a phase 3 trial of troriluzole in adults with SCA (NCT03701399 [Study 206]; n = 217), comprising a subset of patients with the SCA3 genotype (n = 89), the psychometric measurement properties and minimal change thresholds of the FARS-ADL were examined.

RESULTS:

Ceiling effects for the FARS-ADL were absent within the MGH cohort while floor effects were observed for eight of nine items. Excellent internal consistency reliability was observed (α_total = 0.88; α_{items-removed} = 0.86-0.87), and item-to-total correlations were acceptable (r = 0.55-0.89 per item). Convergent and divergent validity were supported with strong correlations demonstrated between FARS-ADL and scales measuring similar concepts (Neuro-QOL [Upper], Neuro-QOL [Lower], PROM-ADL, PROM-PHYS, and FARS-FUNC; all P < 0.001) and weaker correlations shown between measures of differing constructs. A two- to three-point threshold for meaningful changes was supported as 0.5 × SD = 2.43, SEM = 2.19. Mean changes from baseline for subjects classified as "improved," "no change," or "deteriorated" were -0.54, 0.22, and 1.47, respectively. Similar trends were observed in the Study 206 all-SCA and SCA3 cohorts.

CONCLUSION:

Psychometric evaluation showed that the FARS-ADL performed well on analyses examining the reliability and validity of the measure and can detect meaningful changes in patients with SCA, including those with SCA3.

TRIAL REGISTRATION:

ClinicalTrials.gov identifier, NCT03701399 (Study 206).

01 Jan 2025·JOURNAL OF NEUROCHEMISTRY

Troriluzole rescues glutamatergic deficits, amyloid and tau pathology, and synaptic and memory impairments in 3xTg‐AD mice

Article

Author: Perman, Savannah ; Coric, Vladimir ; Pfitzer, Jeremiah ; Suppiramaniam, Vishnu ; Pinky, Priyanka D. ; Reed, Miranda N. ; Redmon, Emma ; Gramlich, Michael W. ; Qureshi, Irfan A. ; Cmelak, Luca

Abstract:

Alzheimer's disease (AD) is a neurodegenerative condition in which clinical symptoms are highly correlated with the loss of glutamatergic synapses. While later stages of AD are associated with markedly decreased glutamate levels due to neuronal loss, in the early stages, pathological accumulation of glutamate and hyperactivity contribute to AD pathology and cognitive dysfunction. There is increasing awareness that presynaptic dysfunction, particularly synaptic vesicle (SV) alterations, play a key role in mediating this early‐stage hyperactivity. In the current study, we sought to determine whether the 3xTg mouse model of AD that exhibits both beta‐amyloid (Aβ) and tau‐related pathology would exhibit similar presynaptic changes as previously observed in amyloid or tau models separately. Hippocampal cultures from 3xTg mice were used to determine whether presynaptic vesicular glutamate transporters (VGlut) and glutamate are increased at the synaptic level while controlling for postsynaptic activity. We observed that 3xTg hippocampal cultures exhibited increased VGlut1 associated with an increase in glutamate release, similar to prior observations in cultures from tau mouse models. However, the SV pool size was also increased in 3xTg cultures, an effect not previously observed in tau mouse models but observed in Aβ models, suggesting the changes in pool size may be due to Aβ and not tau. Second, we sought to determine whether treatment with troriluzole, a novel 3rd generation tripeptide prodrug of the glutamate modulator riluzole, could reduce VGlut1 and glutamate release to restore cognitive deficits in 8‐month‐old 3xTg mice. Treatment with troriluzole reduced VGlut1 expression, decreased basal and evoked glutamate release, and restored cognitive deficits in 3xTg mice. Together, these findings suggest presynaptic alterations are early events in AD that represent potential targets for therapeutic intervention, and these results support the promise of glutamate‐modulating drugs such as troriluzole in Alzheimer's disease. image

01 Aug 2024·Neurology and Therapy

Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis

Article

Author: Perlman, Susan ; Maclaine, Grant D H ; L'Italien, Gilbert J ; Coric, Vladimir ; Khera, Rohan ; Potashman, Michele H ; Schmahmann, Jeremy D ; Beiner, Melissa W ; Oikonomou, Evangelos K

INTRODUCTION:

Traditional methods for assessing movement quality rely on subjective standardized scales and clinical expertise. This limitation creates challenges for assessing patients with spinocerebellar ataxia (SCA), in whom changes in mobility can be subtle and varied. We hypothesized that a machine learning analytic system might complement traditional clinician-rated measures of gait. Our objective was to use a video-based assessment of gait dispersion to compare the effects of troriluzole with placebo on gait quality in adults with SCA.

METHODS:

Participants with SCA underwent gait assessment in a phase 3, double-blind, placebo-controlled trial of troriluzole (NCT03701399). Videos were processed through a deep learning pose extraction algorithm, followed by the estimation of a novel gait stability measure, the Pose Dispersion Index, quantifying the frame-by-frame symmetry, balance, and stability during natural and tandem walk tasks. The effects of troriluzole treatment were assessed in mixed linear models, participant-level grouping, and treatment group-by-visit week interaction adjusted for age, sex, baseline modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA), and time since diagnosis.

RESULTS:

From 218 randomized participants, 67 and 56 participants had interpretable videos of a tandem and natural walk attempt, respectively. At Week 48, individuals assigned to troriluzole exhibited significant (p = 0.010) improvement in tandem walk Pose Dispersion Index versus placebo {adjusted interaction coefficient: 0.584 [95% confidence interval (CI) 0.137 to 1.031]}. A similar, nonsignificant trend was observed in the natural walk assessment [coefficient: 1.198 (95% CI - 1.067 to 3.462)]. Further, lower baseline Pose Dispersion Index during the natural walk was significantly (p = 0.041) associated with a higher risk of subsequent falls [adjusted Poisson coefficient: - 0.356 [95% CI - 0.697 to - 0.014)].

CONCLUSION:

Using this novel approach, troriluzole-treated subjects demonstrated improvement in gait as compared to placebo for the tandem walk. Machine learning applied to video-captured gait parameters can complement clinician-reported motor assessment in adults with SCA. The Pose Dispersion Index may enhance assessment in future research. TRIAL REGISTRATION-CLINICALTRIALS.

GOV IDENTIFIER:

NCT03701399.

News (Medical) associated with Trigriluzole

02 Jun 2025

·www.einpresswire.com

Race to Treat Spinocerebellar Ataxia Accelerates as First Commercial Therapy Nears FDA Nod | DataM Intelligence

The Spinocerebellar Ataxia pipeline is advancing fast as troriluzole nears FDA nod and rivals race with gene and stem cell therapies to seize market edge. Disease modification in spinocerebellar ataxia is shifting from theory to regulatory reality, as precision neurology redefines patient care and market value in rare neurodegenerative diseases.” — DataM Intelligence AUSTIN, TX, UNITED STATES, June 2, 2025 / EINPresswire.com / -- Race to Treat Spinocerebellar Ataxia Accelerates as First Commercial Therapy Nears FDA Nod Spinocerebellar ataxias (SCAs) , a group of rare, inherited neurodegenerative disorders affecting coordination and balance, are finally gaining attention in the biopharmaceutical sector. Characterized by progressive deterioration in the cerebellum and brainstem, SCAs lead to severe mobility impairments and loss of independence—yet until now, there have been no approved treatments to slow or reverse disease progression. That may soon change. Biohaven Pharmaceuticals is leading the charge with its investigational therapy troriluzole, a glutamate modulator now under review by the U.S. Food and Drug Administration. Expected to receive a decision by Q4 2025, troriluzole could become the first approved treatment for SCA, offering symptomatic relief and potential neuroprotective benefits for a condition that affects an estimated 1 to 5 per 100,000 individuals globally. Book Your Free CI Consultation Call: https://www.datamintelligence.com/strategic-insights/ci/spinocerebellar-ataxia Pipeline Momentum: From Broad Therapies to Genetic Precision While Biohaven is poised to be the first commercial entrant, a growing cadre of biotechs are developing precision and platform-based approaches aimed at genetically defined SCAs—particularly SCA1, 2, and 3, which collectively represent the majority of cases. - Vico Therapeutics is advancing VO659, an antisense oligonucleotide targeting the CAG repeat expansion in SCA1 and SCA3. Its genetically guided mechanism offers a scalable template for other polyglutamine disorders. - Sarepta Therapeutics, in collaboration with Arrowhead, is leveraging its RNA therapy platform with SRP-1004 (ARO-ATXN2), a subtype-specific gene silencing agent for SCA2. - Steminent/REPROCELL is gaining traction in Asia with Stemchymal, a regenerative stem cell therapy targeting multiple polyQ SCAs, demonstrating both symptomatic relief and possible disease-modifying activity. Platform vs. Product Strategy: Competing Models Take Shape As SCA emerges as a strategic focus for rare disease pipelines, two distinct development philosophies are forming: 1. First-Mover, Broad Coverage: Biohaven’s approach with troriluzole emphasizes pan-SCA accessibility and immediate market entry, supported by strong U.S. regulatory engagement. 2. Precision, Platform Expansion: Players like Vico and Sarepta are zeroing in on genetic specificity, aligning with scalable RNA-based platforms that could extend into Huntington’s disease and other ataxias. Meanwhile, companies such as Sclnow Biotechnology and PTC Therapeutics are exploring broad neuroprotective or stem cell therapies that may appeal to patients without clearly defined genetic subtypes or in advanced stages of disease. Target Opportunity Profile (TOP): Defining Market Success in SCA For emerging therapies, the Target Opportunity Profile (TOP) sets the benchmark for what it will take to stand out in the evolving SCA market: - Efficacy: A 30% or greater reduction in disease progression (measured by scales like SARA or ICARS), along with sustained improvement over 12–24 months, will be essential. - Safety: Chronic administration with minimal serious adverse events and low immunogenicity will be crucial, particularly for injectable gene therapies. - Mechanism Differentiation: Genetic targeting (ASOs/siRNAs), glutamate modulation, and regenerative strategies aligned to pathophysiology will guide payer and regulatory support. - Patient-Centric Delivery: Oral administration is preferred, though quarterly or monthly intrathecal/IV options remain viable if the benefit justifies the burden. - Economic Value: Orphan pricing ($200,000–$350,000/year) will require clear justification through caregiver burden reduction, delayed disability, and real-world cost offsets. Download Free CI Sample Report: https://www.datamintelligence.com/strategic-insights/sample/spinocerebellar-ataxia Strategic Outlook: A Rare Disease on the Brink of Commercialization The next 12 to 24 months are likely to be transformative for SCA. Biohaven's potential approval will mark a historic milestone, but it is just the beginning. With the convergence of RNA-targeted therapeutics, stem cell platforms, and regulatory momentum, SCA is poised to shift from an underserved indication to a highly competitive and innovation-rich market. As rare neurological diseases become more actionable through genetic insights and targeted delivery, spinocerebellar ataxia represents both a clinical challenge and a high-potential frontier for therapeutic development. Investors, clinical strategists, and portfolio leaders should monitor the space closely—first-mover advantage may offer initial leverage, but long-term success will belong to those who combine precision, scalability, and patient-centered design. Sai Kiran DataM Intelligence 4market Research LLP 877-441-4866 email us here Visit us on social media: LinkedIn X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical StudyOligonucleotideGene Therapy

15 May 2025

·www.fiercebiotech.com

FDA delays decision on Biohaven\'s rare disease drug filing, plans adcomm

Analysts said there will be debate over whether the delay for an approval decision on Biohaven\'s rare disease candidate troriluzole is linked to the FDA layoffs and restructuring.\n Biohaven is giving investors whiplash. Forty-eight hours after saying its filing was on track, the biopharma revealed the FDA has delayed an approval decision on its rare disease candidate troriluzole and plans to hold an advisory committee to discuss the application.Connecticut-based Biohaven made the original statement after the market closed Monday. At that time, the biotech said it had completed a mid-cycle review meeting for troriluzole in the neurodegenerative disease spinocerebellar ataxia, and the FDA had “not conveyed any intention of holding an advisory committee meeting.” The FDA was still on course to make its approval decision in the third quarter.Biohaven provided another update after the market closed Wednesday. By then, the company had heard the FDA is delaying its troriluzole approval decision by three months, pushing the PDUFA date back to the fourth quarter and planning to hold an advisory committee meeting to discuss the application.The company said the delay will “provide time for a full review of Biohaven\'s recent submissions related to information requests from the FDA.” The agency is yet to schedule a date for the advisory committee meeting. William Blair analysts sent a note to investors after talking to Biohaven management, revealing the delay “was triggered by a ‘major amendment’ status, but there was no obvious large body of data submitted for review that would have triggered this.” The analysts said there will be debate over whether the delay is linked to the FDA layoffs and restructuring, but they noted that argenx faced a similar holdup in 2023. The review will provide an early look at how flexible the FDA is willing to be under its new leadership. In 2023, the agency refused to review Biohaven’s filing for approval on the strength of a study that missed its primary endpoint. Biohaven refiled for approval after linking troriluzole to a significant slowing in disease progression in a study that compared people on the drug to patients from a historical study.Patients in the historical study were “rigorously matched” to people taking troriluzole, according to the company. But the failure of troriluzole in the earlier placebo-controlled study provides ammunition for skeptics to question the improvement over historical controls. Shares in Biohaven fell 12% in premarket trading Thursday, slumping to around $17 from a Wednesday closing price of $19.66.

$FDA delays decision on Biohaven\'s rare disease drug filing, plans adcomm$

Accelerated Approval

15 May 2025

·endpoints.news

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Biohaven said late Wednesday that the FDA would be delaying the PDUFA date for its neurodegenerative disease therapy troriluzole and will also require an advisory committee meeting to review the drug. The agency’s move came as a surprise to the company, which had said Monday that “the FDA has not conveyed any intention of holding an advisory committee meeting” for troriluzole. The biotech’s shares $BHVN fell by as much as 14% premarket Thursday. The FDA will decide on troriluzole’s approvability in the rare condition spinocerebellar ataxia (SCA) in the fourth quarter of this year. The panel meeting is yet to be scheduled. Biohaven said that the FDA did not raise any new concerns about the submission, and added that having completed a mid-cycle review, “it does not appear” that a drug safety program or REMS is needed. Analysts from William Blair wrote in a Thursday note that they were also surprised by the delay but not by the adcomm requirement, since troriluzole would be the first FDA-approved therapy for SCA. They added that the need for an adcomm was triggered by a “major amendment” to the approval filing, “but there was no obvious large body of data submitted for review that would have triggered this.” The analysts pointed out that a similar situation had engulfed argenx’s filing for Vyvgart Hytrulo in myasthenia gravis in January 2023. This received a three-month PDUFA extension “despite Argenx management not being able to pinpoint a specific submission triggering the major amendment,” they wrote. Even so, one question for investors — and biotech followers in general — is whether the delay is an upshot of the extensive FDA layoffs orchestrated by the Trump administration. The FDA filing for troriluzole received priority review designation from the FDA just three months ago . This came after Biohaven submitted real-world data indicating that the drug can slow disease progression compared with historical data. An earlier approval application, in 2023, never even made it to the review stage . The Phase 3 trial on which it was based had failed.

Priority ReviewPhase 3Accelerated ApprovalDrug Approval

100 Deals associated with Trigriluzole

External Link

KEGG	Wiki	ATC	Drug Bank
-	Trigriluzole	-	DB15079

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Machado-Joseph Disease	NDA/BLA	United States	Biohaven Ltd.	31 May 2023
Spinocerebellar Ataxias	NDA/BLA	European Union	Biohaven Ltd.	-
Obsessive-Compulsive Disorder	Phase 3	China	Biohaven Pharmaceuticals, Inc.	29 Jan 2021
Obsessive-Compulsive Disorder	Phase 3	Canada	Biohaven Pharmaceuticals, Inc.	29 Jan 2021
Obsessive-Compulsive Disorder	Phase 3	Italy	Biohaven Pharmaceuticals, Inc.	29 Jan 2021
Obsessive-Compulsive Disorder	Phase 3	Netherlands	Biohaven Pharmaceuticals, Inc.	29 Jan 2021
Obsessive-Compulsive Disorder	Phase 3	Spain	Biohaven Pharmaceuticals, Inc.	29 Jan 2021
Obsessive-Compulsive Disorder	Phase 3	United Kingdom	Biohaven Pharmaceuticals, Inc.	29 Jan 2021
Spinocerebellar Ataxia 10	Phase 3	United States	Biohaven Pharmaceuticals, Inc.	08 Mar 2019
Spinocerebellar Ataxia 10	Phase 3	China	Biohaven Pharmaceuticals, Inc.	08 Mar 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06529146 (BHV4157-206-RWE, Company_Website) Manual	Not Applicable	Spinocerebellar Ataxias	-	Troriluzole	ivxejtpicj(zmgoxwmoby) = troriluzole 200 mg dosed orally in patients with SCA met the study's primary endpoint of change from baseline. caluihmodk (mlebcpcjkh ) Met View more	Positive	11 Feb 2025
				external control arm
NCT03701399 (Phase III Clinical Trial of Troriluzole, CTgov)	Phase 3	Spinocerebellar Ataxia 10 \| Machado-Joseph Disease \| Spinocerebellar Ataxia 8	299	troriluzole (Troriluzole)	hiyxxchjhi(nhcnygyjam) = bstweihotz zissoonxza (vrltfdznhk, 0.19) View more	-	10 Feb 2025
				Placebo+troriluzole (Placebo)	hiyxxchjhi(nhcnygyjam) = hfyszntduo zissoonxza (vrltfdznhk, 0.18) View more
NEWS Manual	Phase 3	Spinocerebellar Ataxias	-	Troriluzole	fzgyvgpuzt(cyotdauruv) = Biohaven said that the once-daily oral drug met the primary endpoint across all genotypes of SCA included in the study and that it showed statistically significant superiority after both one and two years compared to the external control groups. pxwnigizqe (xjbnpoxzzm ) Met View more	Positive	23 Sep 2024
AAN2024	Not Applicable	-	-	Troriluzole 200 mg	jditzxlmqz(pmpwngbvma) = values were 40% and 50% higher after troriluzole 100 mg and 280 mg, respectively vs oral riluzole 50 mg ofzeqskjbg (tjvipzwdkw ) View more	-	09 Apr 2024
				Troriluzole 280 mg
AAN2024	Not Applicable	-	-	Troriluzole 140mg QD	ltjhapqggx(eyypbmyhqy) = tfpjohanrq rxgiichyjj (kduaeueqxk ) View more	-	09 Apr 2024
				Troriluzole 200mg QD	ltjhapqggx(eyypbmyhqy) = sptfvhvwad rxgiichyjj (kduaeueqxk ) View more
NCT03701399 (Phase III Clinical Trial of Troriluzole, AAN2024)	Phase 3	Spinocerebellar Ataxias	218	Troriluzole	dqiwhguznn(xyjcizkslm): adj. interaction coefficient = 0.58 (95% CI, 0.14 - 1.03)	Positive	09 Apr 2024
				Placebo
NCT04899921 (CTgov)	Phase 2	Metastatic melanoma	1	Ipilimumab+Troriluzole+Nivolumab (Ipilimumab + Nivolumab + Troriluzole [Phase I Dose Level 1])	yhduqxyrvs(rfokxcdqpw) = teqcsawpap wsvjtfpauq (ujpyobbtem, acldpmmfwg - rufoqgrbwh) View more	-	13 Dec 2023
				Ipilimumab+Troriluzole+Nivolumab (Ipilimumab + Nivolumab + Troriluzole [Phase I Dose Level 2])	yhduqxyrvs(rfokxcdqpw) = hxevenxpys wsvjtfpauq (ujpyobbtem, fizqkgrebv - cstylqubhg) View more
NCT03605667 (T2 Protect AD, CTgov)	Phase 2	Alzheimer Disease	350	Placebo oral capsule	ghsamixsrx(cihxymbuln) = qfuenfrsan hsyqofhboq (mbbtagcfba, wuliehaqpz - levzrvmbcc) View more	-	06 Dec 2023
NCT03299166 (CTgov)	Phase 2/3	Obsessive-Compulsive Disorder	426	Troriluzole (Troriluzole - Randomization Phase)	cvqxqzrzrx(ymwklasltc) = kovvkwwbbd rshmggfyfj (vqkynnqnym, tjisfstynd - yxruwxdwge) View more	-	02 Jun 2023
				placebo+troriluzole (Placebo - Randomization Phase)	cvqxqzrzrx(ymwklasltc) = alwtssvnou rshmggfyfj (vqkynnqnym, yrexvvqdef - eklrfykenz) View more
NCT03829241 (CTgov)	Phase 3	Generalized anxiety disorder	881	Troriluzole (Troriluzole)	akzcvyvqar(gvspiydktv) = ulydtaowln qyxtrehsgh (hqonmgttka, izfrytmlhp - zpkwauvopf) View more	-	28 Dec 2022
				Placebo+Troriluzole (Placebo)	akzcvyvqar(gvspiydktv) = jmagrmqspy qyxtrehsgh (hqonmgttka, tqiddfqlyt - axirhokhrj) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis